UK Regulator Plans New & Higher Fees To Ensure Financial Sustainability
Industry Charges Have Not Been Reviewed Since Brexit
Executive Summary
The MHRA says pharmaceutical and medical device companies should be confident that planned changes to the fees structure will guarantee them “the high-quality service they expect.”
You may also be interested in...
EU To Kick Off ‘Joint Action’ On Tackling Drug Shortages
The joint action on ensuring security of medicines supply will be supported by the EU regulators’ shortages task force, which is to track efforts to coordinate member state activities on the supply and availability of medicines.
Pandemic Treaty: WHO To Broadcast Videos Of Stakeholders ‘Wishlists’
Hundreds of videos have been sent in by people interested in contributing to the future pandemic treaty proposed by the World Health Organization.
EU Preparing Guidance On Synthetic Oligonucleotides & Peptides
Two new quality guidelines are needed to address the increase in applications for clinical trials and marketing authorizations of oligonucleotide- and peptide-based medicines, says the EU regulator.